We are live on ! Find out more
Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Portfolio holdings

AUM $44.6B
1-Year Est. Return 28.94%
This Fund
S&P 500
This Quarter Est. Return
-3.27%
1 Year Est. Return
+28.94%
3 Year Est. Return
+82.62%
5 Year Est. Return
+90.41%
10 Year Est. Return
+293.66%
AUM
$21.8B
AUM Growth
-$587M
Cap. Flow
+$493M
Cap. Flow %
2.27%
Top 10 Hldgs %
19.92%
Holding
3,387
New
221
Increased
1,507
Reduced
1,346
Closed
231

Sector Composition

Rank Sector Weight
1 Technology 9.85%
2 Financials 4.83%
3 Consumer Discretionary 4.67%
4 Healthcare 3.78%
5 Industrials 2.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TISI icon
3076
Team
TISI
$101M
$48K ﹤0.01%
+2,173
New +$22.6K
WPRT
3077
Westport Fuel Systems
WPRT
$34.6M
$48K ﹤0.01%
3,039
+350
+13% +$6.25K
ENDP
3078
DELISTED
Endo International plc
ENDP
$48K ﹤0.01%
20,880
MESO
3079
Mesoblast
MESO
$2.18B
$46K ﹤0.01%
5,500
DHF
3080
BNY Mellon High Yield Strategies Fund
DHF
$175M
$44K ﹤0.01%
15,953
+1,093
+7% +$3.13K
DNA icon
3081
Ginkgo Bioworks
DNA
$486M
$43K ﹤0.01%
+265
New +$51.6K
HIVE
3082
HIVE Digital Technologies
HIVE
$750M
$43K ﹤0.01%
+4,012
New +$41.2K
ISUN
3083
DELISTED
iSun, Inc. Common Stock
ISUN
$43K ﹤0.01%
+10,370
New +$52.5K
GLMD icon
3084
Galmed Pharmaceuticals
GLMD
$4.63M
$42K ﹤0.01%
+145
New +$41.1K
RNXT icon
3085
RenovoRx
RNXT
$50.5M
$42K ﹤0.01%
14,400
ASRT
3086
DELISTED
Assertio
ASRT
$41K ﹤0.01%
949
SAN icon
3087
Banco Santander
SAN
$211B
$41K ﹤0.01%
12,148
+39
+0.3% +$137
CRBP icon
3088
Corbus Pharmaceuticals
CRBP
$189M
$40K ﹤0.01%
2,481
-1,383
-36% -$18.3K
SUPV
3089
Grupo Supervielle
SUPV
$725M
$40K ﹤0.01%
20,000
-2
-0% -$4
HYRE
3090
DELISTED
HyreCar Inc. Common Stock
HYRE
$39K ﹤0.01%
16,180
OGI
3091
Organigram Holdings
OGI
$182M
$38K ﹤0.01%
5,651
+451
+9% +$2.78K
VRPX
3092
DELISTED
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
$38K ﹤0.01%
69
-2
-3% -$1.17K
DMK
3093
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$37K ﹤0.01%
919
-7
-0.8% -$300
ANY icon
3094
Sphere 3D
ANY
$18.3M
$36K ﹤0.01%
248
-107
-30% -$17.4K
SENS icon
3095
Senseonics Holdings Inc
SENS
$419M
$34K ﹤0.01%
866
+21
+2% +$961
VKTX icon
3096
Viking Therapeutics
VKTX
$3.97B
$34K ﹤0.01%
11,313
DHC
3097
Diversified Healthcare Trust
DHC
$2.02B
$33K ﹤0.01%
10,223
+5
+0% +$15
PHX
3098
DELISTED
PHX Minerals
PHX
$33K ﹤0.01%
+10,857
New +$27.7K
SIEN
3099
DELISTED
Sientra, Inc.
SIEN
$33K ﹤0.01%
1,489
ZTEK
3100
Zentek
ZTEK
$79.7M
$32K ﹤0.01%
+10,500
New +$31.8K

Similar funds

Cambridge Investment Research Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Cambridge Investment Research Advisors held 3,387 positions worth $21.8B, down 2.6% from $22.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Cambridge Investment Research Advisors's Q1 2022 filing shows 221 new, 1,507 increased, 1,346 reduced and 231 closed positions. Its largest new stake was Alarm.com: 285,954 shares worth $19M. The largest sale was iShares Core S&P US Growth ETF, an estimated $43.9M.

By sector, the portfolio is most concentrated in Technology at 9.9% of assets, down from 10% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Cambridge Investment Research Advisors's largest Q1 2022 buy was Alarm.com: 285,954 shares worth $19M.
  • Cambridge Investment Research Advisors added most to iShares 0-1 Year Treasury Bond ETF in Q1 2022, an estimated $52.6M increase.
  • Cambridge Investment Research Advisors's biggest Q1 2022 reduction was iShares Core S&P US Growth ETF, cutting an estimated $43.9M.
  • Cambridge Investment Research Advisors fully exited Royal Dutch Shell PLC ADS Class A in Q1 2022, selling an estimated $3.6M.
  • Cambridge Investment Research Advisors's ten largest holdings make up 20% of its $21.8B portfolio in Q1 2022.
  • Cambridge Investment Research Advisors opened 221 new positions and closed 231 in Q1 2022.
  • Cambridge Investment Research Advisors's portfolio value fell 2.6% quarter-over-quarter to $21.8B.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2022, filed 12 May 2022.